Cited 18 times in
Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage IB-IIB cervical cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 금기창 | - |
dc.contributor.author | 이정심 | - |
dc.contributor.author | 김용배 | - |
dc.date.accessioned | 2017-10-26T07:30:35Z | - |
dc.date.available | 2017-10-26T07:30:35Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152123 | - |
dc.description.abstract | OBJECTIVE: We aimed to assess the efficacy of neoadjuvant chemotherapy followed by surgery (NACT+S), and compared the clinical outcome with that of concurrent chemoradiotherapy (CCRT) in patients with International Federation of Gynecology and Obstetrics (FIGO) IB-IIB cervical cancer. METHODS: We reviewed 85 patients with FIGO IB-IIB cervical cancer who received NACT+S between 1989 and 2012, and compared them to 358 control patients who received CCRT. The clinical application of NACT was classified based on the following possible therapeutic benefits: increasing resectability after NACT by reducing tumor size or negative conversion of node metastasis; downstaging adenocarcinoma regarded as relatively radioresistant; and preservation of fertility through limited surgery after NACT. RESULTS: Of 85 patients in the NACT+S group, the pathologic downstaging and complete response rates were 68.2% and 22.6%, respectively. Only two young patients underwent limited surgery for preservation of fertility. Patients of the NACT+S group were younger, less likely to have node metastasis, and demonstrated a higher proportion of FIGO IB cases than those of the CCRT group (p≤0.001). The 5-year locoregional control, progression-free survival, and overall survival rates in the NACT+S group were 89.7%, 75.6%, and 92.1%, respectively, which were not significantly different from the rates of 92.5%, 74%, and 84.9% observed in the CCRT group, respectively (p>0.05). CONCLUSION: NACT+S has no therapeutic advantages over CCRT, the standard treatment. Therefore, NACT+S should be considered only in selected patients through multidisciplinary discussion or clinical trial setting. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Chemoradiotherapy* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hysterectomy* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoadjuvant Therapy* | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Uterine Cervical Neoplasms/diagnosis | - |
dc.subject.MESH | Uterine Cervical Neoplasms/mortality | - |
dc.subject.MESH | Uterine Cervical Neoplasms/pathology | - |
dc.subject.MESH | Uterine Cervical Neoplasms/therapy* | - |
dc.title | Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage IB-IIB cervical cancer | - |
dc.type | Article | - |
dc.publisher.location | Korea (South) | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Radiation Oncology | - |
dc.contributor.googleauthor | Jeongshim Lee | - |
dc.contributor.googleauthor | Tae Hyung Kim | - |
dc.contributor.googleauthor | Gwi Eon Kim | - |
dc.contributor.googleauthor | Ki Chang Keum | - |
dc.contributor.googleauthor | Yong Bae Kim | - |
dc.identifier.doi | 10.3802/jgo.2016.27.e52 | - |
dc.contributor.localId | A03112 | - |
dc.contributor.localId | A00744 | - |
dc.contributor.localId | A00272 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.relation.journalsince | 2011~ | - |
dc.identifier.pmid | 27329200 | - |
dc.relation.journalbefore | ~2010 Korean Journal of Gynecologic Oncology (부인종양) | - |
dc.subject.keyword | Chemoradiotherapy | - |
dc.subject.keyword | Hysterectomy | - |
dc.subject.keyword | Uterine Cervical Neoplasms | - |
dc.contributor.alternativeName | Keum, Ki Chang | - |
dc.contributor.alternativeName | Lee, Jeong Shim | - |
dc.contributor.alternativeName | Kim, Yong Bae | - |
dc.contributor.affiliatedAuthor | Lee, Jeong Shim | - |
dc.contributor.affiliatedAuthor | Kim, Yong Bae | - |
dc.contributor.affiliatedAuthor | Keum, Ki Chang | - |
dc.citation.volume | 27 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 52 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.27(5) : 52, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 46903 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.